C17orf74 Inhibitors

Energy metabolism is a fundamental cellular process, and inhibitors like 2-Deoxy-D-glucose can disrupt this process, which can lead to altered states of protein function, including potentially those of C17orf74. Rapamycin's role in inhibiting the mTOR pathway can also affect the synthesis of proteins, which may include the modulation of C17orf74's expression or stability.

On the other hand, cellular architecture and dynamics are critical for the proper localization and function of proteins. Agents such as Paclitaxel, Blebbistatin, Y-27632, and ML7 interfere with the cytoskeleton and related motor proteins, which may directly or indirectly influence the cellular role of C17orf74, including its trafficking, degradation, or role within specific cellular compartments. Bafilomycin A1's impact on endosomal-lysosomal acidification could affect the degradation route of C17orf74, while signaling pathway modulators like U73122, SB431542, PD98059, Go6983, and LY294002 can alter the intracellular signaling landscape. These modifications can influence the activity of C17orf74, depending on its involvement in these pathways.